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Summary 
Background: Polycystic ovary syndrome (PCOS) is a car-
diometabolic disorder whose features include dyslipidemia,
increased oxidative stress (OS, oxy) and chronic inflamma-
tion. The aim of this study was to investigate the ability of
a summary score for dyslipidemia, OS and inflammation
(the DOI score) to discriminate PCOS patients from healthy
individuals and to evaluate the effect of obesity on individ-
ual scores and the DOI score in patients.
Methods: Lipid status parameters, OS status parameters
(advanced oxidation protein products; total oxidative sta-
tus; prooxidant-antioxidant balance; malondialdehyde;
total protein sulphydryl groups and paraoxonase 1 activity)
and CRP were measured in 114 patients and 50 controls
using standardised assays. The DOI score was calculated
as the sum of dyslipidemia, oxy and inflammation scores,
determined as Z-score values for every subject in relation
to the controls.
Results: PCOS patients had significantly higher oxy-score
compared to controls (P<0.001). In addition, the DOI
Kratak sadr`aj
Uvod: Sindrom policisti~nih jajnika (PCOS) je kardio -
metaboli~ki poreme}aj ~ije su karakteristike dislipidemija,
povi{en oksidativni stres (OS) i hroni~na inflamacija. Cilj
ove studije je bio da se ispita sposobnost zbirnog skora
dislipidemije, OS i inflamacije (DOI skor) da razlikuje pa -
cijentkinje sa PCOS u pore|enju sa zdravim osobama i da
se proceni uticaj gojaznosti na pojedina~ne skorove i DOI
skor kod pacijentkinja.
Metode: Parametri lipidnog statusa, parametri oksidativnog
stresa (uznapredovali produkti oksidacije proteina; ukupni
oksidativni status; prooksidativno-antioksidativni balans;
malon dialdehid; ukupne sulfhidrilne grupe i aktivnost para -
oksonaze 1) i CRP su odre|ivani kod 114 pacijentkinja i 50
kontrolnih ispitanica primenom standardizovanih testova.
DOI skor je izra~unat kao zbir skora dislipidemije, oksi -
dativnog skora i skora inflamacije, odre|en kao vrednosti
Z-skora za svaki subjekt u odnosu na kontrole. 
Rezultati: PCOS pacijentkinje su imale zna~ajno vi{e vred -
nosti oksidativnog skora u pore|enju sa kontrolnom grupom
List of abbreviations: OS, oxidative stress; DOI, dyslipidemia,
oxidative stress, inflammation; CG, control group
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Introduction
Polycystic ovary syndrome (PCOS) is the most
common endocrine disorder in women of reproduc-
tive age (prevalence of 6% – 8%) and is characterised
by reproductive and hyperandrogenic features (1). In
addition to endocrine disturbance, PCOS is a meta-
bolic disorder whose central features are obesity,
insulin resistance, hyperinsulinemia (2), dyslipidemia,
increased oxidative stress (3), chronic inflammation
(4) and subclinical atherosclerosis with a real risk of
future cardiovascular disease (2). 
Dyslipidemia is the most common metabolic
abnormality in PCOS, with a prevalence of up to 70%
according to the National Cholesterol Education
Programme guidelines (lipid levels that are borderline
or elevated) (3). Dyslipidemia usually includes
reduced high-density lipoprotein cholesterol (HDL-C)
and elevated both low-density lipoprotein cholesterol
(LDL-C) and triglycerides. This form of atherogenic
dyslipidemia together with low-grade inflammation
has been associated with insulin resistance (5). Small
dense LDL particles are particularly atherogenic forms
of lipoprotein which may be increased in hyperandro-
genic and insulin resistant PCOS patients (6).
Additionally, elevated levels of oxidised LDL (OxLDL),
a reliable predictor for coronary artery disease (CAD),
have been detected in PCOS patients indicating that
altered lipid metabolism in PCOS is associated with
oxidative stress (OS) (7).
OS is defined as an imbalance between exces-
sive formation of reactive oxygen species (ROS) and
reduced antioxidant defence capacity. It is charac-
terised by irreversible damage of practically all cellular
components leading to impaired cell function. The
pathophysiological mechanism of PCOS remains
vague, but numerous studies have found that PCOS
is associated with OS (8). The potential sources of
ROS in PCOS are adipose tissue, fatty acid oxidation,
hyperglycemia, activity of different enzymes (NADPH
oxidase, xanthine oxidase, an uncoupled state of
endothelial nitric oxidase) and mitochondrial dysfunc-
tion (9). OS is involved in the pathogenesis of insulin
resistance, hyperandogenemia and obesity which
often, but not always, accompany PCOS (9). Several
circulating markers are currently used to assess OS in
PCOS: Homocysteine, malondialdehyde (MDA),
asymmetric dimethylarginine (ADMA), advanced oxi-
dation protein products (AOPPs), superoxide dismu-
tase (SOD), glutathione (GSH) and paraoxonase 1
(PON1) (10). As pronounced OS can arise from
reduced antioxidative protection, it is necessary to
standardize ie measure all the OS parameters in each
individual.
Chronic low-grade inflammation in PCOS
patients is often seen via increased C-reactive protein
(CRP), WBC and IL-18 (11). OS is implicated in the
development of endothelial dysfunction in PCOS,
regardless of obesity and metabolic disturbances
(12). Hyperglycaemia, chronic inflammation and
insulin resistance lead to excessive ROS formation
which exceeds the capacity of cellular antioxidant
defence systems (13). ROS, by activating pro-inflam-
matory signalling pathways in endothelial cells, initi-
ates the development of atherosclerosis (9). 
Within the complex mechanisms mentioned
above the key PCOS risk factors are dyslipidemia, OS
and inflammation. In order to assess their mutual
effects in PCOS, we have calculated a summary score
for dyslipidemia, OS and inflammation (the DOI
score). The aim of this study was to investigate the
ability of a summary DOI score, as a potent indicator
of its interactive role in PCOS, to discriminate patients
from healthy individuals. In addition, we evaluated
the effect of obesity on the values of individual scores
and the DOI score in PCOS patients. 
score was significantly higher in PCOS patients (P<0.001)
as the dyslipidemia (P<0.05) and inflammatory scores
(P<0.001) were greater. According to ROC analysis, the
oxy-score showed better diagnostic accuracy in discriminat-
ing PCOS patients compared to the DOI score (AUC>0.9,
P<0.01). Furthermore, obesity affected the risk scores in
patients, especially the DOI score (significantly higher DOI
scores in such patients, P<0.001). 
Conclusion: PCOS patients had greater dyslipidemia,
chronic inflammation and OS compared to controls and
could be segregated using all four scores. Our data suggest
that weight gain could be the common factor responsible
for induction and propagation of dyslipidemia, OS and
inflammation in PCOS patients.
Keywords: Polycystic ovary syndrome, dyslipidemia,
oxidative stress, inflammation, DOI score, obesity
(P<0,001). Zatim, DOI skor je bio zna~ajno vi{i kod paci-
jentkinja sa PCOS (P<0,001) kao i skorovi dislipidemije
(P<0,05) i inflamacije (P<0,001). Prema rezultatima ROC
analize, oksidativni skor je pokazao bolju dijagnosti~ku
ta~nost u razlikovanju PCOS pacijentkinja u odnosu na
zdrave osobe u pore|enju sa DOI skorom (AUC>0,9,
P<0,01). Osim toga, gojaznost je imala uticaj na vrednosti
skorova rizika, posebno na DOI skor (vrednosti DOI skora
su bile zna~ajno vi{e kod tih pacijentkinja, P<0,001). 
Zaklju~ak: Pacijentkinje sa PCOS su imale izra`eniju dislipi-
demiju, hroni~nu inflamaciju i oksidativni stres u pore|enju
sa kontrolnim ispitanicama i mogu se od njih razlikovati pri-
menom sva ~etiri skora. Na{i rezultati ukazuju da pove -
}anje telesne te`ine mo`e biti zajedni~ki faktor odgovoran
za nastanak i napredovanje dislipidemije, OS i inflamacije
kod pacijentkinja sa PCOS.  
Klju~ne re~i: sindrom policisti~nih jajnika, dislipidemija,
oksidativni stres, inflamacija, DOI skor, gojaznost 
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Materials and Methods
Subjects
The study included 114 PCOS patients (median
age 25.5 years and body mass index, BMI 24.2
kg/m2) and 50 healthy females (median age 28.0
years and BMI 22.1 kg/m2). Samples from all partic-
ipants were collected during a 24-month period
(Octo ber 2015 – June 2017) at the Clinic of Endo -
crinology, Diabetes and Metabolic Diseases, Clinical
Centre of Serbia, Belgrade. Patients included in the
study were referred to endocrinologists because of
menstrual irregularity or hirsutism. PCOS was defined
on the basis of the revised Rotterdam Consensus
Criteria (2003) (14) by meeting 2 of the following 3
criteria: Moderate oligo/amenorrhea (less than eight
menstrual cycles in a year), presence of clinical hyper-
androgenism (hirsutism) and/or biochemical hyper-
androgenemia, and the existence of polycystic ovaries
confirmed by transvaginal ultrasonography. Patients
were analysed during the early follicular phase of the
menstrual cycle, or at any time if they had severe
oligomenorrhea or amenorrhea. 
The control group (CG) consisted of healthy
women (normal glucose metabolism, non-smokers
and zero alcohol consumers) with no signs of hyperan-
drogenism. The presence of hyperprolactinemia,
hypo thyroidism, non-classic 21-hydroxylase deficiency,
Cushing’s disease and androgen-secreting tu mours in
the CG were excluded by laboratory tests. CG females
had not taken oral contraceptives, glucocorticoids or
antiandrogens in the previous three months. The study
was approved by the Institute’s Ethics Committee and
conducted respecting the principles set out in the
latest amendment to the De cla ration of Helsinki
(Edinburgh, 2000). Written infor med consent was vol-
untary obtained from all subjects. The study protocol
was evaluated and approved by Ethics Committee of
the Faculty of Medicine and Faculty of Pharmacy,
University of Belgrade.
Methods
BMI and systolic and diastolic arterial blood
pressure (SBP and DBP) were determined in all study
participants. BMI was calculated as the ratio of body
weight and body height squared. SBP and DBP were
measured using a mercury sphygmomanometer on
the left arm in a sitting position. The average of two
measurements was calculated and used for analysis.
Blood samples were collected in the morning
after a 12 h fasting period in the follicular phase of
the cycle (on the 2nd or the 3rd day) from both the
PCOS patients and the CG or randomly in the case of
severe oligomenorrhoea or amenorrhea (in PCOS
patients). Plasma and serum were separated and
stored at -80 °C until analyses took place.
Total cholesterol (TC), HDL-C, triglyceride (TG)
and CRP concentration were determined using com-
mercially available enzymatic and turbidimetric tests
on an automated biochemical analyser Dimension
RxL Max (Siemens Healthcare GmbH, Germany).
The concentration of LDL-C was calculated by the
Friedewald formula (15). NonHDL-C (total choles-
terol minus HDL-C) and the TG-to-HDL-C ratio
(TG/HDL-C) were also determined in all study partic-
ipants.
Advanced oxidation protein products (AOPP)
were determined according to the Witko-Sarsat
method using a reaction with glacial acetic acid and
potassium iodide (16). Total oxidative status (TOS)
was measured by a spectrophotometric method using
o-dianisidine optimized by Erel (17). Total antioxida-
tive status (TAS) was measured by a spectrophoto-
metric method using ABTS as a chromogen (18). The
method for prooxidant-antioxidant balance (PAB)
used 3,3’, 5,5’-tetramethylbenzidine as a chromo gen
(19). Malondialdehyde (MDA) was measured by
spectrophotometry using the thiobarbituric acid-re -
active substances (TBARS) assay (20). Total protein
sulphydryl (SH-) groups were determined using a
spectrophotometric method with 5,5’-dithiobis (2-
nitro benzoic acid) (DTNB) (21). Superoxide dismu-
tase (SOD) activity was measured according to a
method which depended on the ability of the enzyme
to inhibit autooxidation of epinephrine in alkaline
medium (22). PON1 activity was measured kinetically
using paraoxon (Chem Service, PA, USA) as the sub-
strate by the method described by Richter and Fur -
long (23). All assays were performed on a Ilab 300+
(Instrumentation Laboratory, Milan, Italy). 
As we wished to examine the mutual effect of
the most important risk factors in PCOS patients, we
calculated the DOI score as a sum of dyslipidemia,
OS and inflammatory scores. To calculate the dyslipi-
demia score we standardised all the variables by cal-
culating Z scores for LDL-C, TG and HDL-C using
mean and standard deviation calculated from the CG.
Thereafter, the dyslipidemia score was calculated
according to the equation: Average of the standard-
ised variables (LDL-C+TG)/2 minus standardised
HDL-C. The OS score (oxy-score) was calculated by
subtracting the protective score from the damage
score using the equation given by Veglia et al. (24).
The protective score was calculated as an average of
standardised antioxidant variables (total SH-groups,
TAS, SOD and PON1 activity) while the damage
score was calculated as an average of standardised
prooxidant factors (AOPP, TOS, PAB and MDA). The
inflammation score was determined in both groups
after standardisation of CRP as an acute phase pro-
tein. All variables with non-normal distributions were
log-transformed before computation.
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Statistical analysis 
Statistical analysis was performed using the Sta -
tistical Package for the Social Sciences (version18.0
for Windows, SPSS Inc., Chicago, IL, USA). Since the
variables did not show normal Gaussian distributions
the data are shown as median and interquartile range
and comparisons between groups were made using
the Mann-Whitney U or Kruskal-Wallis tests. Spear -
man’s correlation analysis was used to evaluate the
strength of association between the scores and multi-
ple linear regression analysis was implemented to
determine the mutual influence of obesity, lipid and
OS parameters in PCOS patients. Areas under receiv-
er operating characteristic curves (AUC-ROC) for the
dyslipidemia, oxy, inflammation and summary DOI
scores were calculated and the discriminative abilities
of the models were classified according to their AUC
values as poor (0.5≤AUC<0.7), acceptable (0.7≤
AUC<0.8), excellent (0.8≤AUC<0.9) or outstand-
ing (AUC≥0.9). A P value <0.05 was considered sta-
tistically significant. 
Results
The characteristics of the PCOS patients and CG
subjects are presented in Table I. 
The results are shown as the median values and
interquartile range. After Mann-Whitney analysis, the
following results were observed. HDL-C was signifi-
cantly lower in PCOS patients compared to the CG.
TC, nonHDL-C, LDL-C and TG did not significantly
differ between the two groups. The atherogenic index
(TG/HDL-C ratio) did not significantly differ between
the two groups (even though the median value of the
TG/HDL ratio was higher in PCOS patients). PCOS
patients had significantly higher CRP compared to the
CG.
OS parameters in PCOS patients and the CG are
presented in Figure 1.
Significantly higher prooxidant parameters
(AOPP, TOS, PAB and MDA) were found in PCOS
patients compared to the CG. PCOS patients had
lower PON1 activity (P<0.05) and reduced concen-
tration of SH-groups (P<0.001), parameters of
antioxidant protection, compared to the CG.
In order to assess the influence and extent of
OS, dyslipidemia and inflammation in PCOS we cal-
culated the oxy-score, a comprehensive index of OS
status, dyslipidemia and inflammation scores as well
as a summary DOI score (Figure 2). 
As expected PCOS patients had a significantly
higher oxy-score compared to the CG (the damage
score was higher in PCOS patients and the protective
score was lower in PCOS patients). The DOI score
were higher in PCOS patients as the values  of the dys-
lipidemia and inflammatory scores were higher than
those in the CG. 
Interrelationships between the different scores
were assessed using Spearman’s correlation analysis
and are shown in Table II.
The oxy-score showed the strongest and most
significant positive correlation with the dyslipidemia
score (r<0.001) and significant positive correlation
with the inflammation score (r<0.01). In addition,
strong positive association was observed between the
dyslipidemia and the inflammation scores (r<0.001).
Table I Basic socio-demographic, clinical and biochemical data from the PCOS patients and the CG.
Parameter PCOS (n=114) Control group (CG) (n=50) P
BMI, kg/m2 24.2 (21.2–29.7) 22.1 (20.7–23.5) <0.01
Age, years 25.5 (22.0–29.2) 28.0 (23.7–30.0) 0.177
SBP, mmHg 120 (110–125) 110 (103–120) <0.01
DBP, mmHg 75.0 (70.0–80.0) 74.5 (65.7–80.0) 0.371
TC, mmol/L 4.76 (4.14–5.31) 4.98 (4.38–5.50) 0.232
HDL–C, mmol/L 1.40 (1.10–1.80) 1.60 (1.32–1.95) <0.01
nonHDL–C, mmol/L 3.24 (2.57–3.93) 3.39 (2.87–3.76) 0.653
LDL–C, mmol/L 2.84 (2.19–3.28) 2.81 (2.53–3.12) 0.789
TG, mmol/L 0.840 (0.657–1.42) 0.930 (0.712–1.37) 0.745
TG/HDL–C 0.644 (0.387–1.20) 0.503 (0.401–0.876) 0.173
CRP, mg/L 1.90 (0.70–3.70) 0.55 (0.40–1.00) <0.001
P<0.05; <0.01; <0.001
Data are presented as median and interquartile range
Continuous variables were compared using the Mann-Whitney U test
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Figure 1 OS parameters in PCOS patients and the CG.
***P<0.001, *P<0.05 compared to PCOS patients, according to the Mann-Whitney U test 
Figure 2 Risk scores (dyslipidemia, inflammation and oxy scores) in PCOS patients and the CG. 
***P<0.001, *P<0.05 compared to the PCOS patients
Multiple linear regression analysis (MLR) backward
selection, was implemented to determine the mutual
influence of obesity, lipid and OS parameters in PCOS
patients. The best models which determined variabil-
ity in the distinct scores are shown in Table III.
The main oxy-score predictors in PCOS patients
were TC (positive correlation) and HDL-C (negative
correlation). The adjusted R2 was 0.228 which indi-
cated that approximately 23% of variability in oxy-
score values was related to the selected parameters
model. The most important predictors of the inflam-
mation score were BMI and MDA (both with positive
correlation, with 27% of variation). The dyslipidemia
score was defined by BMI, AOPP, MDA (positive cor-
relations) and TOS (negative correlation). This model
explained 54% of influence on score variability.
J Med Biochem 2018; 37 (4) 481








Table II Spearman’s nonparametric correlation of risk scores
in PCOS patients.
Unstandardized beta coefficient (SE-Standard error); 95th CI; *P<0.05, **P<0.01, ***P<0.001 according MLR analysis
AUC – Area Under the Curve, P from ROC analysis – signifi-
cance of the specific curve
†,††, ††† – Significantly different from Oxy-score; ‡,‡‡,‡‡‡ –
Significantly different from DOI score; P<0.05, 0.01, 0.001
Table III MLR analysis for predictors of oxy, inflammation and dyslipidemia score.
Table IV AUC for calculated scores after constructing ROC curves.
Oxy-score Inflammation score Dyslipidemia score
B (SE) 95th CI B (SE) 95th CI B (SE) 95th CI 
BMI / 0.080(0.013) (0.055-0.105)*** 0.144 (0.022) (0.100 – 0.188)***
TC 1.843(0.394) (1.062 – 2.623)*** / /
HDL-C -2.911(0.806) (-4.509 – -1.313)*** / /
AOPP / / 0.049 (0.007) (0.035 – 0.062)***
TOS / / -0.018(0.007) (-0.032 – -0.005)**
MDA / 0.123 (0.057) (0.009 – 0.236)* 0.271(0.108) (0.0058 – 0.4840)*
Adjusted R2 0.228 0.270 0.539 
Variable(s) AUC (SE) 95th CI P
Oxy-score 0.996 (0.002) 0.992–1.001 <0.001
DOI score 0.972 (0.009) †† 0.953–0.990 <0.001
Inflammation
score 0.751 (0.037) 
†††,‡‡‡ 0.679–0.823 <0.001
Dyslipidemia
score 0.603 (0.041) 
†††,‡‡‡ 0.522–.685 <0.05
Figure 3 ROC curves for calculated scores as markers of
PCOS.
In order to evaluate the ability of all the scores
to identify PCOS patients, we performed ROC curve
analysis (Figure 3) and compared the scores using
their AUC values (Table IV). 
Both, oxy and DOI scores had larger AUCs
(AUC > 0.9) compared to the inflammation and dys-
lipidemia scores meaning that these two scores exhib-
ited outstanding discriminitive abilities. This is sup-
ported by the high sensitivity (97%) and specificity
(97%) of the oxy-score and also the sensitivity (88%)
and specificity (88%) for the DOI score at the cut-off
value. Interestingly, the oxy-score showed better diag-
nostic accuracy in discriminating PCOS patients
(P<0.01) compared to the DOI score. 
As multiple regression analysis indicated that
BMI was an important predictor for both inflammato-
ry and dyslipidemia scores, we examined how obesity
affected all the risk scores in PCOS patients. We divid-
ed the PCOS patients into three subgroups according
to BMI values. The first subgroup consisted of normal
weight patients (BMI<25 kg/m2), the second group
consisted of overweight patients (BMI=25.1–30.0
kg/m2) and the third group consisted of obese
patients (BMI>30.0 kg/m2) (Table V).
Normal weight PCOS patients had significantly
lower dyslipidemia and inflammation scores com-
pared to both overweight and obese patients. The
calculated DOI score in normal weight PCOS patients
compared to both overweight and obese patients was
also significantly lower, while their oxy-score level did
not differ from obese patients, but it was significantly
lower compared to overweight PCOS patients. When
risk scores between overweight and obese PCOS
patients were examined only the inflammation score
differed (significantly higher in obese PCOS patients). 
Discussion
It was shown that PCOS clinical characteristics:
dyslipidemia, increased OS and chronic inflammation
can promote dysregulation of the ovarian thecal com-
partment and endothelial dysfunction resulting in
hyperandrogenism, anovulation and early atheroscle-
rosis (3). In the current study, by using specific bio-
chemical indices, we have examined the ability of a
summary score for dyslipidemia, OS and inflamma-
tion (the DOI score) to discriminate PCOS patients,
prone to develop cardiometabolic consequences,
from healthy females. 
Dyslipidemia is the most common metabolic
abnormality in PCOS patients, although the extent
and type of dyslipidemia is variable (3). Dyslipidemia
is characterised by significantly lower HDL, a lipopro-
tein that is thought to be the strongest metabolic pre-
dictor of coronary heart disease (25) and hypertriglyc-
eridemia which has been found in both younger and
older age groups (5, 26). However, some investi -
gators have not found differences in circulating lipid
levels in women with PCOS when compared with
BMI-matched controls (27). In our study, we found
de creased HDL-C concentration in PCOS patients
compared to the CG, without any significant differ-
ence in TG, nonHDL-C and the atherogenic index
(Table I). Furthermore, TC and LDL-C were not
increased in PCOS patients (Table I). There is wide
variability of data in studies regarding LDL-C in PCOS
patients. Several studies have reported increased
LDL-C and alterations in LDL quality in PCOS
patients. LDL consists of different subclasses accord-
ing to size, density and atherogenicity. Small dense
LDL particles are more atherogenic then large buoy-
ant ones and there is continuous increase in the LDL
atherogenicity with decreasing particle size in PCOS
patients (3, 28). However, all of the above-mentioned
studies included primarily overweight or obese PCOS
patients. A Korean study (29) revealed that there
were no significant quantitative or qualitative changes
in the LDL profile of non-obese PCOS patients. A
large meta study (30) indicated that LDL-C was sig-
nificantly elevated in PCOS patients, but also that
LDL-C was influenced by many variables, including
ethnicity, severity of syndrome (anovulatory vs. ovula-
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Table V Risk scores in obesity-related sub-groups of PCOS patients.
Parameter




PCOS, BMI > 30.0 kg/m2
(n=35)
P
Dyslipidemia score -1.29 (-2.34 – -0.09) 1.13 (0.19 – 2.71) ††† 1.74 (0.39 – 2.81) ††† < 0.001 
Inflammation score -0.23 (-0.80 – 0.93) 0.79 (-0.04 – 1.13) † 1.25 (0.75 – 1.67) †††,‡ < 0.001 
Oxy-score 9.37 (7.17 – 13.40) 12.31 (9.88 – 15.91) †† 10.88 (7.79 – 14.17) < 0.001 
DOI score 7.92 (5.05 – 12.48) 14.30 (11.54 – 19.77) ††† 14.56 (9.31 – 18.01) †† < 0.001 
†,††, ††† – Significantly different from the first group (PCOS normal weight group) 
‡,‡‡,‡‡‡ – Significantly different from the second group (PCOS overweight group)
P<0.05, 0.01, 0.001
tory forms), quality of food and BMI. However, after
calculating the dyslipidemia score, we found a signif-
icantly higher score in PCOS patients compared to
the CG although only HDL-C was significantly lower
in PCOS patients, while other lipid parameters did not
differ between the examined groups (Figure 2). HDL
particles prevent LDL particle oxidation and have anti-
atherogenic and anti-inflammatory properties. It has
been suggested that PCOS patients not only have
decreased HDL-C but also altered HDL quality (31).
Decreased HDL2 subfraction (the most anti-athero-
genic HDL subtype) has been observed in PCOS
patients (25). We can assume that decreased HDL-C
and changed composition of HDL-C particles repre-
sents the initial step in the development of dyslipi-
demia in PCOS patients. Moreover, it could also be
associated with propagation of OS and inflammation,
as a consequence of the reduced anti-oxidative and
anti-inflammatory capacity of low HDL-C. 
Inflammation is clearly involved in the initiation
and progression of atherosclerosis and there is a close
relationship between chronic inflammation and OS in
the atherosclerotic pathological process (32). Obesity
affects cardiovascular risk in PCOS patients because it
promotes chronic low-grade inflammation causing an
increase in inflammatory markers (CRP, TNF-  and IL-
6) (33). There is direct correlation between the levels
of inflammatory markers in PCOS and patient BMI, as
overweight and obese PCOS patients have signifi-
cantly higher levels of these markers compared to
weight-matched controls (34). Our results incorporat-
ing the inflammatory marker CRP, a powerful inde-
pendent predictor of CVD, confirmed this. CRP levels
were significantly higher in our PCOS patients com-
pared to the CG, but the values were lower than 3.5
mg/L which indicated low-grade inflammation.
Regarding that, the inflammation score was signifi-
cantly higher in PCOS patients compared to the CG.
OS has been recognised as an undesirable fac-
tor present in various pathological disorders including
PCOS. Serum prooxidants and antioxidants are
altered in PCOS patients, causing redox imbalance
and promotion of OS. PCOS patients have increased
OS markers such as MDA, the end-product of lipid
peroxidation, reflecting oxidative-induced cell dam-
age. AOPP, a marker of oxidant-mediated protein
damage and a potent inflammatory mediator, total
oxidant status (TOS), an aggregative index of plasma
oxidant state and prooxidant-antioxidant balance
(PAB), a parameter reflecting concomitant existance
of prooxidants and antioxidants in living systems have
all been found to be elevated in PCOS patients (10,
35, 36). Our current observations (Figure 1) concur
with previous data. PCOS patients have diminished
antioxidative protection parameters such as PON1
(an antioxidant enzyme) and total SH-groups as scav-
engers of free radicals (10, 37). The first study report-
ing reduced serum PON1 activity in PCOS patients
was a study by Dursun et al. (38). The authors sug-
gested that decreased serum PON1 activity may have
contributed to increased susceptibility towards the
development of insulin resistance and atherosclerotic
heart disease in PCOS patients. Another study (39)
also showed that PCOS patients had reduced antiox-
idant PON1 activity and suggested that they were
oxidatively stressed which may have been related to
increased atherosclerosis seen later in life. Our PCOS
patients had both decreased PON1 activity as well as
SH-groups compared to the CG (Figure 1). The exact
mechanism behind decreased PON1 in PCOS
patients is not known. Reduced PON1 can contribute
to OS because PON1 is an antioxidative enzyme that
prevents oxidation of lipoproteins by hydrolysing
atherogenic products of oxidative lipid modification
(10). In order to assess OS we used the oxy-score, a
comprehensive index of OS derived from computa-
tion of different variables relevant for oxidative bal-
ance (24). 
As several risk factors are intimately involved in
complex PCOS pathology we combined three of them
and calculated the DOI score (sum of dyslipidemia,
oxy and inflammation scores). As expected, all scores
were significantly increased in PCOS patients com-
pared to the CG (Figure 2). Since the values of all
three scores were increased in PCOS patients, the
DOI score was significantly higher in PCOS patients,
indicating the usefulness of this result for assessing
cardiometabolic risk factors in PCOS patients.
A direct correlation between obesity and both
insulin resistance and OS in PCOS patients has been
demonstrated (40). OS participates in the pathogen-
esis of obesity mainly by inducing chronic inflamma-
tion and adipose tissue dysfunction (41). Further -
more, it appears that both adipose tissue dysfunction
and obesity promote dyslipidemia, chronic inflamma-
tion and OS. The main predictors of the oxy-score in
our PCOS patients were TC (positive correlation) and
HDL-C (negative correlation). The most important
pre dictors of the inflammation score in our PCOS
patients were BMI and MDA (both with positive cor-
relation), while independent factors of the dyslipi-
demia score in our PCOS patients were BMI, AOPP
and MDA (positive correlation) and TOS (negative
correlation) (Table III). AUC-ROC analysis revealed
that both the oxy- and the summary DOI scores were
outstanding cardiovascular risk indices for PCOS
patient outcomes (Table IV). 
The effect of obesity on markers of OS, inflam-
mation and dyslipidemia in PCOS patients has been
widely examined (42). In our study BMI was an in -
dependent predictor of both dyslipidemia and in -
flammation scores, as opposed to the oxy-score
whose independent predictors were TC and HDL-C.
Following on from this, overweight and obese PCOS
patients had significantly higher dyslipidemia and
inflammatory scores as well as the DOI score when
compared to normal weight subjects (Table V).
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Adipose tissue is a dynamic endocrine organ that is
involved in the secretion of different hormones and
cyto kines. Functional abnormalities of adipocytes are
observed in PCOS patients. These abnormalities can
promote mild inflammation and OS due to hypertro-
phy when exposed to androgen excess (9). These
hypertrophic adipocytes have been identified as a
source of proinflammatory cytokines that are potent
stimulators of ROS and low-grade inflammation (3).
Together our data suggest that weight gain could be
the common factor responsible for induction and
propagation of dyslipidemia, OS and inflammation in
PCOS patients.
In conclusion, our results indicate that PCOS
patients display more pronounced dyslipidemia,
chronic inflammation and OS compared to the CG
and can be segregated by the dyslipidemia, oxy and
inflammation scores. The summary DOI score, as
well as the oxy-score, show remarkable abilities to
identify PCOS patients (AUC 0.9, which is outstand-
ing diagnostic accuracy), compared to the inflamma-
tion and dyslipidemia scores. 
Our mode of assessment is relevant and applica-
ble for cardiovascular risk prediction. In order to
achieve further solid conclusions our study must be
extended prospectively in order to monitor progres-
sion of dyslipidemia, inflammation and OS parame-
ters via the DOI score and to assess the effect of ther-
apy on reducing the overall cardiovascular risk in the
PCOS patients later in their life. 
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